Beam Therapeutics BEAM
$20.90 −$0.04 (-0.19%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $21.66 +3.65%
Open$20.60
Prev close$20.94
Day range$20.54 – $22.10
Volume3.89M
Market cap$2.16B
P/E (TTM)–
Dividend yield–
BEAM Stock News
Headlines matching Beam Therapeutics or the BEAM ticker, most recent first.
- JonesTrading Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $35
- A Quick Look at Today's Ratings for Beam Therapeutics(BEAM.US), With a Forecast Between $35 to $80
- H.C. Wainwright Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $80
- Shimizu has added a 1.5-hour fire-resistant specification to its Hi-Wood Beam product lineup.
- J.P. Morgan Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Announces Target Price $44
- A Quick Look at Today's Ratings for Beam Therapeutics(BEAM.US), With a Forecast Between $43 to $78
- A Quick Look at Today's Ratings for Beam Therapeutics(BEAM.US), With a Forecast Between $35 to $78
- Freedom Capital Markets Downgrades Beam Global(BEEM.US) to Hold Rating, Maintains Target Price $1.5 Negative
- Maxim Group Maintains Beam Global(BEEM.US) With Buy Rating, Cuts Target Price to $3 Negative
- BofA Securities Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $47
- HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target
- 4: Beam Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Evans John M.
- Freedom Capital Markets Initiates Beam Global(BEEM.US) With Buy Rating, Announces Target Price $1.5
- Wells Fargo Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $70
- Wedbush Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $65
No comments yet — be the first to weigh in on BEAM.
Sign in to join the discussion.